

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for	form 1449A/P	то		Complete if Known		
					Application Number	09/194,356	
				LOSURE	Filing Date	September 2, 1999	
STATEMENT BY APPLICANT					First Named Inventor	Dario NERI et al.	
					Group Art Unit	1642 1643	
	(us	e as many s	heets as ne	cessary)	Examiner Name	Alana M. Harris	
_	Sheet	<u>_</u>	of	1	Attorney Docket Number	ELLIS-0003	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	۲,
amh	1	MATSUURA et al., "The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma," Proc.Natl.Acad.Sci., vol. 82, pp 6517-6521, October 1985.	
	2	MATSUURA et al., "An α-N-Acetylgalactosaminylation at the Threonine Residue of a Defined Peptide Sequence Creates the Oncofetal Peptide Epitope in Human Fibronectin," The Journal of Biological Chemistry, vol. 264, no. 18, pp 10472-10476, 1989.	
7	3	MATSUURA et al., "The Oncofetal Structure of Human Fibronectin Defined by Monoclonal Antibody FDC-6," The Journal of Biological Chemistry, vol. 263, No. 7, pp 3314-3322, 1988.	
V	4	ISEMURA et al., "Isolation and Characterization of Human Placenta Fibronectin," J.Biochem. 96, 163-169, 1984.	
	<u> </u>		
<u>.</u>			

	1			
Examiner Signature	anthorn	Date Considered	12/19/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.